The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis

Published:2023-01-23 Issue:6 Volume:44 Page:2121-2129
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Boz Cavit^ORCID,Ozakbas Serkan,Terzi Murat,Karabudak Rana,Sevim Serhan,Turkoglu Recai,Soysal Aysun,Balcı Belgin Petek,Efendi Hüsnü,Turan Ömer Faruk,Yüceyar Nur,Yetkin Mehmet Fatih,Karahan Serap Zengin,Demirkıran Meltem,Guler Sibel,Agan Kadriye,Kıylıoğlu Nefati,Baba Cavid,Tuncer Asli,Köseoğlu Mesrure

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-023-06608-z.pdf

Reference28 articles.

1. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 365(14):1293–1303

2. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362(5):387–401

3. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 376(3):221–234

4. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 354(9):899–910

5. Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G et al (2016) Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler. 22(10):1315–1326

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fingolimod real life experience in non-naive multiple sclerosis patients;The European Research Journal;2024-09-04

2. Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08

3. A case study: ADEM-like lesions as a first clinical event in highly active multiple sclerosis;2024-04-19

4. Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report;Frontiers in Neurology;2024-02-29

5. Natural compounds as potential therapeutic candidates for multiple sclerosis: Emerging preclinical evidence;Phytomedicine;2024-01